Final answer:
The accuracy of the claim regarding 47 states with laws about the availability of epinephrine auto-injectors in schools during Mylan's EpiPen acquisition is uncertain without current data. Epinephrine auto-injectors, such as EpiPens, are life-saving devices for individuals with severe allergic reactions. The recent news on Mylan and EpiPen centers around ethical debates on drug pricing after notable price increases in 2016.
Step-by-step explanation:
As for the statement about 47 states having laws about making epinephrine auto-injectors available at school, I do not have current data confirming the exact number of states with such laws during the time of Mylan acquisition of the EpiPen. It is true, however, that many states have laws regarding the availability of EpiPens in schools to protect students with severe allergies. These laws are critical because EpiPens are devices preloaded with epinephrine, a drug that can rapidly stop a life-threatening anaphylactic reaction to allergens such as shellfish, peanuts, bee stings, or certain medications. Epinephrine works by raising blood pressure and relaxing bronchial smooth muscle, counteracting the life-threatening effects of anaphylaxis. The accessibility of these auto-injectors in educational settings can be a matter of life and death for individuals prone to severe allergic reactions.
When discussing Mylan and the EpiPen, recent news has highlighted the controversy over price hikes in 2016 and subsequent backlash for what many saw as greed from the pharmaceutical company. This led to public outrage, the introduction of a less expensive generic version, and investigations into possible antitrust violations. The controversy sparked debates on the ethics of drug pricing and the responsibilities of pharmaceutical companies in ensuring the availability of life-saving medications.